Phosphatidylinositol-glycan-specific phospholipase D is an enzyme that in humans is encoded by the GPLD1gene.[5][6]
Many proteins are tethered to the extracellular face of eukaryotic plasma membranes by a glycosylphosphatidylinositol (GPI) anchor. The GPI-anchor is a glycolipid found on many blood cells. The protein encoded by the GPLD1 gene is a GPI degrading enzyme that hydrolyzes the inositol phosphate linkage in proteins anchored by phosphatidylinositol glycans, thereby releasing the attached protein from the plasma membrane.[6]
Plasma concentrations of Gpld1 in mice were found to increase after exercise and to correlate with improved cognitive function, and concentrations of GPLD1 in blood were increased in active elderly humans.[7][8]
Jinnai H, Nakamura S (August 1999). "Characterization of phospholipase D activation by GM2 activator in a cell-free system". The Kobe Journal of Medical Sciences. 45 (3–4): 181–90. PMID10752311.
Tang J, Li W (2002). "[Methodological study on the assay of glycosylphosphatidylinositol-specific phospholipase D activity in serum]". Hunan Yi Ke da Xue Xue Bao = Hunan Yike Daxue Xuebao = Bulletin of Hunan Medical University. 24 (2): 119–22. PMID11938765.
Slomiany A, Nishikawa H, Slomiany BL (March 2002). "Screening and modulation of extracellular signals by mucous barrier. Serum glycosylphosphatidylinositol phospholipase D (GPI-PLD) releases protective mucous barrier from oral mucosa". Journal of Physiology and Pharmacology. 53 (1): 21–38. PMID11939716.
Jaworek J, Bonio J, Leja-Szpa A, Nawrot K, Tomaszewska MR, Stachura J, et al. (March 2002). "Sensory nerves in central and peripheral control of pancreatic integrity by leptin and melatonin". Journal of Physiology and Pharmacology. 53 (1): 51–74. PMID11939719.
Deeg MA, Bowen RF (2002). "Phosphorylation decreases trypsin activation and apolipoprotein al binding to glycosylphosphatidylinositol-specific phospholipase D". Biochemistry and Cell Biology. 80 (2): 253–60. doi:10.1139/o02-004. PMID11989719.
Xiaotong H, Hannocks MJ, Hampson I, Brunner G (2002). "GPI-specific phospholipase D mRNA expression in tumor cells of different malignancy". Clinical & Experimental Metastasis. 19 (4): 291–9. doi:10.1023/A:1015545407700. PMID12090469. S2CID2868010.
Magnusson P, Sharp CA, Farley JR (November 2002). "Different distributions of human bone alkaline phosphatase isoforms in serum and bone tissue extracts". Clinica Chimica Acta; International Journal of Clinical Chemistry. 325 (1–2): 59–70. doi:10.1016/S0009-8981(02)00248-6. PMID12367767.
Tang JH, Gu SL, Zhang XJ (April 2001). "[Preliminary study of the gene structure of human glycosylphosphatidylinositol specific phospholipase D]". Hunan Yi Ke da Xue Xue Bao = Hunan Yike Daxue Xuebao = Bulletin of Hunan Medical University. 26 (2): 95–7. PMID12536633.
Kurtz TA, Fineberg NS, Considine RV, Deeg MA (February 2004). "Insulin resistance is associated with increased serum levels of glycosylphosphatidylinositol-specific phospholipase D". Metabolism. 53 (2): 138–9. doi:10.1016/j.metabol.2003.09.004. PMID14767861.
Lugli EB, Pouliot M, Portela M, Loomis MR, Raper J (November 2004). "Characterization of primate trypanosome lytic factors". Molecular and Biochemical Parasitology. 138 (1): 9–20. doi:10.1016/j.molbiopara.2004.07.004. PMID15500911.
Everett PB, Senogles SE (November 2004). "D3 dopamine receptor activates phospholipase D through a pertussis toxin-insensitive pathway". Neuroscience Letters. 371 (1): 34–9. doi:10.1016/j.neulet.2004.08.033. PMID15500962. S2CID27173449.